Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: Identification of L611S alone and in cis with V617F in polycythemia vera

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2479-2486

  Nussenzveig, Roberto H ^a   Burjanivova, Tatiana ^b   Salama, Mohamed E ^a   Ogilvie, Natalie W ^a   Marcinek, Juraj ^b   Plank, Lukas ^b   Agarwal, Archana M ^a   Perkins, Sherrie L ^a   Prchal, Josef T ^a,c  

^a ARUP LABORATORIES   (United States)

^b Physics and Informatics   (Slovakia)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

FFPE; High resolution melt; JAK2 exon 12; JAK2 exon 14; Mutation detection; Myeloproliferative neoplasm; Polycythemia vera

Indexed keywords

DNA; FORMALDEHYDE; JANUS KINASE 2; PARAFFIN;

ARTICLE; BLOOD; BONE MARROW BIOPSY; CODON; CONTROLLED STUDY; DNA ISOLATION; EXON; GENE DUPLICATION; GENE IDENTIFICATION; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; LEUKOCYTE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; BIOPSY; BONE MARROW; DNA MUTATIONAL ANALYSIS; EXONS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MICROTOMY; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID DENATURATION; PARAFFIN EMBEDDING; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84868370152     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.697562     Document Type: Article

References (28)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061. (Pubitemid 40386783)
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397. (Pubitemid 40544655)
5. Cleyrat C, Jelinek J, Girodon F, et al. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 2010;24:1069-1073.
6. Kratz CP, Boll S, Kontny U, et al. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381-383. (Pubitemid 43148689)
7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468. (Pubitemid 46193073)
8. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097. (Pubitemid 47281402)
9. Lippert E, Girodon F, Hammond E, et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009;94:38-45.
10. Carillo S, Henry L, Lippert E, et al. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of jak2 exon 12 mutations-clinical relevance in the monitoring of polycythemia. J Mol Diagn 2011;13:263-270.
11. Er TK, Lin SF, Chang JG, et al. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 2009;408:39-44.
12. Qian J, Lin J, Yao DM, et al. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clin Chim Acta 2010;411:2097-2100.
13. Rapado I, Grande S, Albizua E, et al. High resolution melting analysis for JAK2 exon 14 and exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009;11:155-161.
14. Ugo V, Tondeur S, Menot ML, et al. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One 2010; 5:e8893.
15. Gundry CN, Dobrowolski SF, Martin YR, et al. Base-pair neutral homozygotes can be discriminated by calibrated high-resolution melting of small amplicons. Nucleic Acids Res 2008;36:3401-3408. (Pubitemid 351859007)
16. Dwight Z, Palais R, Wittwer CT. uMELT: prediction of highresolution melting curves and dynamic melting profiles of PCR products in a rich web application. Bioinformatics 2011;27:1019-1020.
17. Burjanivova T, Marcinek J, Lasabova Z, et al. A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients. Diagn Mol Pathol 2009;18:108-111.
18. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32-38.
19. Funakoshi-Tago M, Tago K, Sumi K, et al. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. J Biol Chem 2009;284:12680-12690.
20. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006;125:625-633.
21. Olsen RJ, Dunphy CH, O'Malley DP, et al. The implication of identifying JAK2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. J Hematop 2008;1:111-117.
22. Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 2006;130: 997-1003. (Pubitemid 44061430)
23. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006;108:2173-2181. (Pubitemid 44497497)
24. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86:668-676.
25. Funakoshi-Tago M, Pelletier S, Moritake H, et al. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 2008;28:1792-1801.
26. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009;11:49-53.
27. Reading NS, GC, Prchal JT. Rapid and sensitive detection and identification of JAK2 exon 12 mutations in V617F-negative myeloproliferative disorders by polymerase chain reaction. Presented at Association for Molecular Pathology meeting. 2009. Kissimmee, FL.
28. Laughlin TS, Moliterno AR, Stein BL, et al. Detection of exon 12 mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. J Mol Diagn 2010;12: 278-282.